SCHEMBL3563114

SCHEMBL3563114

O=C(O)CCS(=O)(=O)O.[NaH].[NaH]

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 2/20 0.60
LMNA P02545 5/20 0.44
EGLN1 Q9GZT9 2/20 0.44
ALKBH5 Q6P6C2 1/20 0.44
SUCNR1 Q9BXA5 1/20 0.44
PTGS1 P23219 1/20 0.41
PDE4A P27815 1/20 0.41
SLC6A6 P31641 1/20 0.41
CYP2C19 P33261 1/20 0.41
BLM P54132 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.40
TSHR P16473 2/20 0.38
NFKB1 P19838 1/20 0.38
PMP22 Q01453 1/20 0.38
APP P05067 1/20 0.38
FFAR3 O14843 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL513587 0.97
Ethane SCHEMBL28162037 0.92 APEX1 (0.57) APEX1LMNAEGLN1ALKBH5SUCNR1
Acetic Acid SCHEMBL10800063 0.90 APEX1 (0.50) APEX1LMNAEGLN1ALKBH5SUCNR1
Adipic Acid SCHEMBL10904206 0.89 LMNA (0.58) APEX1LMNAPDE4ABLMSLC22A6
Mercaptopropionic Acid SCHEMBL6689886 0.85 PTGS1 (0.52) APEX1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL5022360 0.83 LMNA (0.50) APEX1LMNAEGLN1ALKBH5SUCNR1
Methacrylic Acid SCHEMBL1881169 0.81 APEX1 (0.46) APEX1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL513001 0.80 LMNA (0.53) APEX1LMNAEGLN1ALKBH5SUCNR1
SCHEMBL7098500 0.79 TSHR (0.57) LMNAPDE4ASLC22A6TSHRNFKB1
SCHEMBL16719244 0.79 TSHR (0.57) LMNAPDE4ASLC22A6TSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662854-B2 HIF hydroxylase inhibitors ISIS INNOVATION LIMITED (GB) 2010-02-16 US disclosed
US-7638295-B2 Identifying agent which modulates 2-oxoglutarate dependent oxygenase; ankyrin substrate; hypoxia-inducible factor; thalassemia ISIS INNOVATION LIMITED (GB) 2009-12-29 US disclosed
EP-2065366-A2 HIF hydroxylase inhibitors ISIS Innovation Limited (GB) 2009-06-03 EP disclosed
EP-1485347-B1 HIF HYDROXYLASE INHIBITORS FOR USE IN THE TREATMENT OF ANAEMIA ISIS INNOVATION (GB) 2009-04-29 EP disclosed
US-20080227848-A1 Assays ISIS INNOVATION LIMITED (GB) 2008-09-18 US disclosed
EP-1466927-B1 PROCESS FOR PRODUCTION OF CARBOXYLIC ACID POLYMERS KAO CORP (JP) 2007-03-28 EP disclosed
US-20070066576-A1 HIF hydroxylase inhibitors ISIS INNOVATION LIMITED (GB) 2007-03-22 US disclosed
EP-1733030-A2 ASSAYS FOR IDENTIFYING MODULATORS OF THE HYDROXYLATION OF ANKYRIN REPEAT PROTEINS BY 2-OXOGLUTARATE DEPENDENT OXYGENASE AND METHODS OF USING THE SAME ISIS INNOVATION LIMITED (GB) 2006-12-20 EP disclosed
US-20050227948-A1 Hif hydroxylase inhibitors ISIS INNOVATION LIMITED (GB) 2005-10-13 US disclosed
WO-2005093411-A2 ASSAYS FOR IDENTIFYING MODULATORS OF THE HYDROXYLATION OF ANKYRIN REPEAT PROTEINS BY 2-OXOGLUTARATE DEPENDENT OXIGENASE AND METHODS OF USING THE SAME ISIS INNOVATION LIMITED (GB) 2005-10-06 WO disclosed
EP-1485347-A2 HIF HYDROXYLASE INHIBITORS ISIS INNOVATION LIMITED (GB) 2004-12-15 EP disclosed
EP-1466927-A1 PROCESS FOR PRODUCTION OF CARBOXYLIC ACID POLYMERS Kao Corporation (JP) 2004-10-13 EP disclosed
WO-2003080566-A2 HIF HYDROXYLASE INHIBITORS ISIS INNOVATION LIMITED (GB) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227948-A1 Hif hydroxylase inhibitors HIF1AN, HIF1A, EGLN3 APEX1 1504/4885LMNA 3704/4885EGLN1 5/4885
US-20070066576-A1 HIF hydroxylase inhibitors HIF1AN, HIF1A, EGLN3 APEX1 1504/4885LMNA 3704/4885EGLN1 5/4885
US-20080227848-A1 Assays OGDH, HOGA1, OXGR1 APEX1 137/4885LMNA 2834/4885EGLN1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.